Literature DB >> 7578856

Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis.

U Picillo1, S Migliaresi, M R Marcialis, A M Ferruzzi, G Tirri.   

Abstract

One hundred and three patients suffering from systemic sclerosis (SSc), with different extent of skin involvement, were retrospectively examined to investigate the correlations between clinical manifestations and anticardiolipin antibodies (aCL). aCL of IgG, IgA, and IgM classes were measured in the patients' sera by enzyme linked immunosorbent assay. aCL were found in 26 patients (25.2%). A significant association was found between aCL and myocardial ischaemia or necrosis (p = 0.011). No patient showed the clinical picture of the antiphospholipid syndrome. On the basis of clinical manifestations, a protocol for disease score was drawn. Patients with IgG-aCL and with IgA-aCL showed a disease score higher than aCL negative patients (p = 0.008 and p = 0.022 respectively). Thus, the finding of aCL can be considered a useful serological index for the most severe forms of SSc.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578856     DOI: 10.3109/08916939508993333

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  11 in total

1.  Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome.

Authors:  Pollyanna d'Ávila Leite; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-04-09       Impact factor: 2.631

2.  Clinical setting of patients with systemic sclerosis by serum autoantibodies.

Authors:  U Picillo; S Migliaresi; M R Marcialis; A M Ferruzzi; G Tirri
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

Review 3.  Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders.

Authors:  Saion Chatterjee; John D Pauling
Journal:  Clin Rheumatol       Date:  2020-09-21       Impact factor: 2.980

Review 4.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

5.  [Unclear hip pain in systemic sclerosis. Osteonecrosis].

Authors:  M Buslau; D Spitzenberger
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

6.  Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis.

Authors:  Ewa Wielosz; Magdalena Dryglewska; Maria Majdan
Journal:  Clin Rheumatol       Date:  2009-05-13       Impact factor: 2.980

Review 7.  Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Silvia Piantoni; Rossella Reggia; Francesca Dall'Ara; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

Review 8.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 9.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

10.  Antiphospholipid antibodies and systemic scleroderma.

Authors:  Awa Oumar Touré; Fatimata Ly; Abibatou Sall; Alassane Diatta; Macoura Gadji; Moussa Seck; Blaise Faye; Tandakha Dieye; Saliou Diop
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.